European Journal of Breast Health
Original Article

The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial

1.

Department of Radiology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey

2.

Department of Oncology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey

3.

Department of General Surgery, İstanbul Taksim Training and Research Hospital, İstanbul, Turkey

4.

Department of General Surgery, Biruni University School of Medicine, İstanbul, Turkey

5.

Department of Physical Therapy and Rehabilitation, Demiroğlu Bilim University School of Medicine, İstanbul, Turkey

6.

Department of Radiation Oncology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey

7.

Department of Physical Therapy and Rehabilitation, Bilgi University, İstanbul, Turkey

8.

Department of Pathology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey

9.

Department of General Surgery, Memorial Etiler Hospital, İstanbul, Turkey

10.

Department of Obstetrics and Gynecology, İstanbul Florence Nightingale Hospital, İstanbul, Turkey

11.

Department of General Surgery, İstanbul Florence Nightingale Hospital, İstanbul, Turkey

Eur J Breast Health 2020; 16: 177-182
DOI: 10.5152/ejbh.2020.5114
Read: 62 Downloads: 38 Published: 24 June 2020

Objective: Premenopausal women with breast cancer are at risk of developing ovarian failure after chemotherapy. The aim of this study was to investigate the negative effects of systemic chemotherapy on ovarian function in premenoupausal women with breast cancer.

Materials and Methods: Thirty-one premenopausal women with operable breast cancer aged between 26-48 years were enrolled in this prospective cohort study to investigate preliminary results. Additional 69 patients’ data will be included after the completion of all five measurements. The change in serum Antimullerian Hormone (AMH) levels, mean ovarian volumes (MOV) and antral follicle counts (AFCs) at 3–month intervals were recorded to evaluate ovarian function. Women who had at least one pretreatment and four post-treatment measurements in one year follow-up period were included in the study. Decision of chemotherapy regimen was taken by the Tumor Board.

Results: Thirty-one patients had all five AMH, MOV and AFCs results. There was a statistically significant negative correlation between 1st - 5th AMH levels (p=0.006) and 1st - 5th AFCs during the follow-up period (p<0.0001). However pre- and post-chemotherapy measurements of MOVs did not demonstrate any significant correlation (p=0.799). BMI, parity, lactation, histopathology and molecular subtypes of breast cancer, alcohol intake, smoking and type of chemotherapy regimen were not significantly correlated with AMH, AFC and MOV.

Conclusion: Pretreatment AMH levels and AFC were shown to have a significant role in early prediction of ovarian-reserve after chemotherapy.

Cite this articles as: Çelebi F, Ordu Ç, İlgün S, Öztürk A, Erdoğan İyigün Z, Alço G, et al. The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial. Eur J Breast Health 2020; 16(3): 177-182

Files
EISSN 2587-0831